分子生物标志物与诊断杂志

Neurology has traditionally relied on clinical symptoms, neuroimaging and electrophysiological studies to diagnose and manage brain disorders. However, the complexity and heterogeneity of these conditions often pose significant challenges. Recent advances in molecular biology have introduced molecular biomarkers as a powerful tool, revolutionizing our understanding and treatment of neurological diseases. Molecular biomarkers are measurable indicators of a biological state or condition. In neurology, they can be proteins, nucleic acids, lipids, metabolites, or other molecules found in blood, cerebrospinal fluid, or brain tissue. These biomarkers can provide valuable information about disease mechanisms, progression and response to treatment.

The pursuit of precision medicine has long been a goal. Traditional cancer treatments often used a uniform approach, effective for some but inadequate for many. Yet, technological advances and molecular biomarkers have revolutionized cancer diagnosis and treatment. These molecular signals enable tailored therapies, enhancing outcomes and patient care. Precision oncology is a transformative strategy considering each patient's tumour's unique molecular features. Unlike the old one-size-fits-all approach, it personalizes treatment based on specific genetic changes fuelling tumour progression. By harnessing molecular biomarkers, clinicians can better understand the underlying biology of cancer and identify targeted therapies that offer the greatest chance of success.

Diagnostic pathology, traditionally reliant on microscopic examination of tissue samples for disease identification, has undergone a profound transformation with the emergence of molecular biomarkers. These biomarkers, which include genetic mutations, proteins and other molecular signatures, have revolutionized the way diseases are diagnosed, classified and treated. The primary goal of diagnostic pathology is to provide accurate and timely diagnoses to help clinicians manage patients effectively. By studying the cellular and molecular characteristics of tissues, pathologists can identify the presence of abnormal changes indicative of disease. These findings are often reported in pathology reports, which serve as essential tools for clinicians in formulating treatment plans and monitoring patient progress.

In modern medicine, integrating molecular biomarkers has dramatically transformed drug development and therapeutic strategies. These biomarkers, which reflect biological processes or responses to treatment, provide critical insights into disease mechanisms, patient stratification, and treatment outcomes. They include a range of molecules like DNA, RNA, proteins and metabolites, circulating tumour cells, and imaging features. These diverse biomarkers offer valuable information for diagnosing, predicting, and monitoring diseases. Advances in comics technologies—such as genomics, transcriptomics, proteomics, and metabolomics—allow researchers to thoroughly analyse biomarker profiles linked to diseases and drug responses. Through advancements in omits technologies such as genomics, transcriptomics, proteomics and metabolomics, researchers can comprehensively characterize biomarker profiles associated with disease states and drug responses.